Collision tumors are rare entities that consist of at least two or more histologically and ontologically distinct tumor types within the same organ. It is still not well understood how collision tumors form; yet, three main theories have been proposed to explain the pathogenesis, including the "random collision effect," "field cancerization," and "tumor-to-tumor carcinogenesis." Collision tumors have been encountered in various body organs, including the lung. They either consist of a metastasizing tumor colliding with primary cancer or distinct primary or metastatic cancers colliding together. Here, we describe a rare case of collision tumors of the lung that consists of two metastatic carcinomas, namely renal cell carcinoma and urothelial carcinoma of the bladder. We propose that the urothelial carcinoma disseminated into several pre-existing pulmonary metastases of renal cell carcinoma with heterotopic bone formation. The possible mechanisms underlying the development of this peculiar tumor are discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718149PMC
http://dx.doi.org/10.1016/j.rmcr.2020.101297DOI Listing

Publication Analysis

Top Keywords

collision tumors
20
urothelial carcinoma
12
renal cell
12
cell carcinoma
12
tumors lung
8
carcinoma heterotopic
8
collision
6
carcinoma
6
lung case
4
case report
4

Similar Publications

A collision tumor is a rare neoplastic lesion consisting of two or more coexisting, distinct cell line entities. In this report, we present the case of a 56-year-old male patient with a history of colon cancer who presented to the emergency room with visual deficits that had started about eight months earlier. An ophthalmologic examination reported left homonymous hemianopsia, prompting a brain MRI, which showed a right posterior temporal extra-axial mass concerning intracerebral metastatic colon cancer, in consideration of patient history.

View Article and Find Full Text PDF

This manuscript reports the case of a 75-year-old patient presenting with a collision tumor consisting of a pancreatic neuroendocrine tumor and intra-ampullary adenocarcinoma, which manifested with obstructive jaundice and was treated with primary surgical cytoreduction. Additionally, a bibliographic search of original articles was performed in the Medical Literature Analysis and Retrieval System Online (MEDLINE; via PubMed) and the Latin American and Caribbean Literature on Health Sciences (LILACS) databases to review the literature on pancreaticobiliary collision tumors. Currently, information regarding pancreatic and bile duct collision tumors is limited due to their very low incidence.

View Article and Find Full Text PDF

Glycosylation is one of the most prevalent and crucial protein modifications. Quantitative site-specific characterization of glycosylation usually requires sophisticated intact glycopeptide analysis using glycoproteomics. Recent efforts have focused on the interrogation of intact glycopeptide analyses using tandem mass spectrometry.

View Article and Find Full Text PDF

Background: Pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are rare malignancies affecting the pancreas. The World Health Organization defines MiNENs as neoplasms composed of morphologically recognizable neuroendocrine and non-neuroendocrine components, each constituting 30% or more of the tumor volume. Adenocarcinoma-neuroendocrine carcinoma is the most frequent MiNEN combination.

View Article and Find Full Text PDF

Background: The coexistence of two or more distinct neoplasms within the same anatomical site characterizes collision tumors. While the presence of dual tumors is frequently observed in esophageal cases, the simultaneous occurrence of three distinct tumor types is extremely rare, posing significant challenges for pathological evaluation and diagnosis. Surgical resection remains the primary treatment, with generally favorable outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!